2026 Q3 - tulosraportti
Tänään
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 453 | ||
| 51 | ||
| 296 | ||
| 495 | ||
| 181 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 18.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 28.10. | ||
2026 Q2 - tulosraportti 29.7. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 18.2. | ||
2025 Q3 - tulosraportti 29.10.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·3 t sittenStronger krone wiped out Photocure's sales growth Photocure, which trades in dollars and euros, but reports in kroner, is hit by a strengthened krone. https://medwatch.no/nyheter/legemidler_biotek/article19776525.ece
Yes now it is the crown's fault !!There is always a "problem" in Photocure.... Lately it has been the Chinese who have screwed them over and won't pay the Milestone. What will be next...!?!
·4 t sittenPhotocure upgrades growth expectations for 2026 today at 08:35 ∙ News Overview (AI) Photocure has upgraded its full-year revenue growth expectations, driven by increasing adoption of the company's bladder cancer diagnostic technology. Although the third-quarter result was impacted by acquisition costs and currency headwinds, prompting an analyst to lower the target price, the company remains optimistic. Strategic initiatives include the appointment of a new CFO and preparation for the launch of the company's newly acquired molecular test. Photocure raised its product revenue growth expectations for 2026 to 10-12 % at constant exchange rates, up from the previous estimate of 8-11 %. For the third quarter of 2026, total revenue rose to 140.9 million NOK, while adjusted EBITDA fell slightly to 18.5 million NOK, and EBIT fell to minus 3.4 million NOK due to acquisition costs. The company appointed Dennis Camporeale as CFO and granted him 200,000 share options at an exercise price of 54.98 NOK. ABG Sundal Collier lowered its target price for Photocure to 70 NOK from 75 NOK, citing the acquisition of Vesica Health and negative currency effects, while maintaining a Buy recommendation. Photocure expects the first revenues in 2027 from AssureMDx, a non-invasive molecular test acquired from Vesica Health, with expected reimbursement in the first half of 2027.
·1 päivä sitten · MuokattuCevira has after the rollout in June until September almost sold for 100 million kroner already, this will be good. This is just China, soon Europe and other markets will come in addition. Milestones and royalties will be hailing in going forward.
·9.10.Lau Svenssen suggests a value of 120-150 kroner, but believes shareholders should demand more in the event of a takeover. https://svenssentudborg.dk/photocure-en-lille-aktie-med-store-ambitioner/ Photocure: A small stock with big ambitions Lau Svenssen October 8, 2026 In the video here, Svenssen gives his assessment of Photocure, which operates in a niche market, has international growth opportunities and is a potential takeover candidate. Photocure is a smaller company in the portfolio, but according to Svenssen's assessment, one of the more interesting ones. The company works with light-based diagnostics of bladder cancer and also has a development project within the treatment of cervical cancer. The long-term investment case is mainly about expanding the existing business internationally and gaining greater traction in the US market. The US is central to growth Photocure already has a good position in Europe, but US sales are, according to the analysis, only about half as large as the European ones. This stands in contrast to the general ratio in the pharmaceutical industry, where the US normally constitutes a larger market than Europe. A larger US business is therefore a central part of the company's growth opportunities. In the longer term, Asia, South America and other markets can also contribute as health systems develop. Photocure is at the same time a company that invests in its own development. Earnings are therefore normally only slightly above zero, even though the company is not fundamentally a loss-making business. Challenges with devices and deliveries A significant challenge has been the sales of the devices necessary to use the company's technology. Coatings and deliveries... China and Asieris can become decisive In my assessment, the most interesting part of the investment case is the cooperation with the Chinese partner Asieris. Asieris has completed a development project within a light-based treatment of cervical cancer. According to the analysis, the project was approved in China in March, which was supposed to trigger a milestone payment to Photocure. The payment has, however, become a point of contention. Photocure has not received the amount that the company, in my opinion, believes it is entitled to. This creates uncertainty about both the financial outcome of the cooperation and the further relationship between the two companies. A possible international potential If the treatment can be brought further to other markets, it can open up a significant new earnings opportunity. According to Svenssen, a step has also been taken towards the US market, where Asieris has obtained FDA approval to conduct a phase 3 study. However, it is important to distinguish between permission to conduct a clinical study and final approval for marketing. There are still development and commercial uncertainties. Can Photocure be acquired? The conflict with Asieris gives rise to considering whether Photocure can become an acquisition candidate. My interpretation is therefore that Asieris might be trying to pressure Photocure in order to be able to take over the entire business at a low price. That interpretation is at my own expense. This makes Photocure a possible acquisition candidate. The company finds itself in an unusual situation. I imagine that we can get between 120 and 150 NOK for the share. We ought to get much more if Asieris (or whoever might be behind it) tries to take over everything at a low price. Svenssen thus sees a possible price potential and has himself invested in Photocure. However, it is an investment where the time horizon can be long and where the outcome depends on several uncertain conditions: international growth, device deliveries, the agreement with Asieris and the development of the treatment in new markets. The potential must be seen in the context of the significant risks.
Lau Svenssen can gladly get mine for a price within that interval. Actually for a price in the lower part of the interval. And it can be had today. Then he avoids sitting and waiting for shares at that price.
·9.10.Lau Svenssen wrote an equity review yesterday with many interesting observations regarding Photocure. The article can be read on Svenssen & Tudborg.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
Tänään
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·3 t sittenStronger krone wiped out Photocure's sales growth Photocure, which trades in dollars and euros, but reports in kroner, is hit by a strengthened krone. https://medwatch.no/nyheter/legemidler_biotek/article19776525.eceYes now it is the crown's fault !!There is always a "problem" in Photocure.... Lately it has been the Chinese who have screwed them over and won't pay the Milestone. What will be next...!?!
- ·4 t sittenPhotocure upgrades growth expectations for 2026 today at 08:35 ∙ News Overview (AI) Photocure has upgraded its full-year revenue growth expectations, driven by increasing adoption of the company's bladder cancer diagnostic technology. Although the third-quarter result was impacted by acquisition costs and currency headwinds, prompting an analyst to lower the target price, the company remains optimistic. Strategic initiatives include the appointment of a new CFO and preparation for the launch of the company's newly acquired molecular test. Photocure raised its product revenue growth expectations for 2026 to 10-12 % at constant exchange rates, up from the previous estimate of 8-11 %. For the third quarter of 2026, total revenue rose to 140.9 million NOK, while adjusted EBITDA fell slightly to 18.5 million NOK, and EBIT fell to minus 3.4 million NOK due to acquisition costs. The company appointed Dennis Camporeale as CFO and granted him 200,000 share options at an exercise price of 54.98 NOK. ABG Sundal Collier lowered its target price for Photocure to 70 NOK from 75 NOK, citing the acquisition of Vesica Health and negative currency effects, while maintaining a Buy recommendation. Photocure expects the first revenues in 2027 from AssureMDx, a non-invasive molecular test acquired from Vesica Health, with expected reimbursement in the first half of 2027.
- ·1 päivä sitten · MuokattuCevira has after the rollout in June until September almost sold for 100 million kroner already, this will be good. This is just China, soon Europe and other markets will come in addition. Milestones and royalties will be hailing in going forward.
- ·9.10.Lau Svenssen suggests a value of 120-150 kroner, but believes shareholders should demand more in the event of a takeover. https://svenssentudborg.dk/photocure-en-lille-aktie-med-store-ambitioner/ Photocure: A small stock with big ambitions Lau Svenssen October 8, 2026 In the video here, Svenssen gives his assessment of Photocure, which operates in a niche market, has international growth opportunities and is a potential takeover candidate. Photocure is a smaller company in the portfolio, but according to Svenssen's assessment, one of the more interesting ones. The company works with light-based diagnostics of bladder cancer and also has a development project within the treatment of cervical cancer. The long-term investment case is mainly about expanding the existing business internationally and gaining greater traction in the US market. The US is central to growth Photocure already has a good position in Europe, but US sales are, according to the analysis, only about half as large as the European ones. This stands in contrast to the general ratio in the pharmaceutical industry, where the US normally constitutes a larger market than Europe. A larger US business is therefore a central part of the company's growth opportunities. In the longer term, Asia, South America and other markets can also contribute as health systems develop. Photocure is at the same time a company that invests in its own development. Earnings are therefore normally only slightly above zero, even though the company is not fundamentally a loss-making business. Challenges with devices and deliveries A significant challenge has been the sales of the devices necessary to use the company's technology. Coatings and deliveries... China and Asieris can become decisive In my assessment, the most interesting part of the investment case is the cooperation with the Chinese partner Asieris. Asieris has completed a development project within a light-based treatment of cervical cancer. According to the analysis, the project was approved in China in March, which was supposed to trigger a milestone payment to Photocure. The payment has, however, become a point of contention. Photocure has not received the amount that the company, in my opinion, believes it is entitled to. This creates uncertainty about both the financial outcome of the cooperation and the further relationship between the two companies. A possible international potential If the treatment can be brought further to other markets, it can open up a significant new earnings opportunity. According to Svenssen, a step has also been taken towards the US market, where Asieris has obtained FDA approval to conduct a phase 3 study. However, it is important to distinguish between permission to conduct a clinical study and final approval for marketing. There are still development and commercial uncertainties. Can Photocure be acquired? The conflict with Asieris gives rise to considering whether Photocure can become an acquisition candidate. My interpretation is therefore that Asieris might be trying to pressure Photocure in order to be able to take over the entire business at a low price. That interpretation is at my own expense. This makes Photocure a possible acquisition candidate. The company finds itself in an unusual situation. I imagine that we can get between 120 and 150 NOK for the share. We ought to get much more if Asieris (or whoever might be behind it) tries to take over everything at a low price. Svenssen thus sees a possible price potential and has himself invested in Photocure. However, it is an investment where the time horizon can be long and where the outcome depends on several uncertain conditions: international growth, device deliveries, the agreement with Asieris and the development of the treatment in new markets. The potential must be seen in the context of the significant risks.Lau Svenssen can gladly get mine for a price within that interval. Actually for a price in the lower part of the interval. And it can be had today. Then he avoids sitting and waiting for shares at that price.
- ·9.10.Lau Svenssen wrote an equity review yesterday with many interesting observations regarding Photocure. The article can be read on Svenssen & Tudborg.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 453 | ||
| 51 | ||
| 296 | ||
| 495 | ||
| 181 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 18.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 28.10. | ||
2026 Q2 - tulosraportti 29.7. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 18.2. | ||
2025 Q3 - tulosraportti 29.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
Tänään
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 18.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 28.10. | ||
2026 Q2 - tulosraportti 29.7. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 18.2. | ||
2025 Q3 - tulosraportti 29.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·3 t sittenStronger krone wiped out Photocure's sales growth Photocure, which trades in dollars and euros, but reports in kroner, is hit by a strengthened krone. https://medwatch.no/nyheter/legemidler_biotek/article19776525.eceYes now it is the crown's fault !!There is always a "problem" in Photocure.... Lately it has been the Chinese who have screwed them over and won't pay the Milestone. What will be next...!?!
- ·4 t sittenPhotocure upgrades growth expectations for 2026 today at 08:35 ∙ News Overview (AI) Photocure has upgraded its full-year revenue growth expectations, driven by increasing adoption of the company's bladder cancer diagnostic technology. Although the third-quarter result was impacted by acquisition costs and currency headwinds, prompting an analyst to lower the target price, the company remains optimistic. Strategic initiatives include the appointment of a new CFO and preparation for the launch of the company's newly acquired molecular test. Photocure raised its product revenue growth expectations for 2026 to 10-12 % at constant exchange rates, up from the previous estimate of 8-11 %. For the third quarter of 2026, total revenue rose to 140.9 million NOK, while adjusted EBITDA fell slightly to 18.5 million NOK, and EBIT fell to minus 3.4 million NOK due to acquisition costs. The company appointed Dennis Camporeale as CFO and granted him 200,000 share options at an exercise price of 54.98 NOK. ABG Sundal Collier lowered its target price for Photocure to 70 NOK from 75 NOK, citing the acquisition of Vesica Health and negative currency effects, while maintaining a Buy recommendation. Photocure expects the first revenues in 2027 from AssureMDx, a non-invasive molecular test acquired from Vesica Health, with expected reimbursement in the first half of 2027.
- ·1 päivä sitten · MuokattuCevira has after the rollout in June until September almost sold for 100 million kroner already, this will be good. This is just China, soon Europe and other markets will come in addition. Milestones and royalties will be hailing in going forward.
- ·9.10.Lau Svenssen suggests a value of 120-150 kroner, but believes shareholders should demand more in the event of a takeover. https://svenssentudborg.dk/photocure-en-lille-aktie-med-store-ambitioner/ Photocure: A small stock with big ambitions Lau Svenssen October 8, 2026 In the video here, Svenssen gives his assessment of Photocure, which operates in a niche market, has international growth opportunities and is a potential takeover candidate. Photocure is a smaller company in the portfolio, but according to Svenssen's assessment, one of the more interesting ones. The company works with light-based diagnostics of bladder cancer and also has a development project within the treatment of cervical cancer. The long-term investment case is mainly about expanding the existing business internationally and gaining greater traction in the US market. The US is central to growth Photocure already has a good position in Europe, but US sales are, according to the analysis, only about half as large as the European ones. This stands in contrast to the general ratio in the pharmaceutical industry, where the US normally constitutes a larger market than Europe. A larger US business is therefore a central part of the company's growth opportunities. In the longer term, Asia, South America and other markets can also contribute as health systems develop. Photocure is at the same time a company that invests in its own development. Earnings are therefore normally only slightly above zero, even though the company is not fundamentally a loss-making business. Challenges with devices and deliveries A significant challenge has been the sales of the devices necessary to use the company's technology. Coatings and deliveries... China and Asieris can become decisive In my assessment, the most interesting part of the investment case is the cooperation with the Chinese partner Asieris. Asieris has completed a development project within a light-based treatment of cervical cancer. According to the analysis, the project was approved in China in March, which was supposed to trigger a milestone payment to Photocure. The payment has, however, become a point of contention. Photocure has not received the amount that the company, in my opinion, believes it is entitled to. This creates uncertainty about both the financial outcome of the cooperation and the further relationship between the two companies. A possible international potential If the treatment can be brought further to other markets, it can open up a significant new earnings opportunity. According to Svenssen, a step has also been taken towards the US market, where Asieris has obtained FDA approval to conduct a phase 3 study. However, it is important to distinguish between permission to conduct a clinical study and final approval for marketing. There are still development and commercial uncertainties. Can Photocure be acquired? The conflict with Asieris gives rise to considering whether Photocure can become an acquisition candidate. My interpretation is therefore that Asieris might be trying to pressure Photocure in order to be able to take over the entire business at a low price. That interpretation is at my own expense. This makes Photocure a possible acquisition candidate. The company finds itself in an unusual situation. I imagine that we can get between 120 and 150 NOK for the share. We ought to get much more if Asieris (or whoever might be behind it) tries to take over everything at a low price. Svenssen thus sees a possible price potential and has himself invested in Photocure. However, it is an investment where the time horizon can be long and where the outcome depends on several uncertain conditions: international growth, device deliveries, the agreement with Asieris and the development of the treatment in new markets. The potential must be seen in the context of the significant risks.Lau Svenssen can gladly get mine for a price within that interval. Actually for a price in the lower part of the interval. And it can be had today. Then he avoids sitting and waiting for shares at that price.
- ·9.10.Lau Svenssen wrote an equity review yesterday with many interesting observations regarding Photocure. The article can be read on Svenssen & Tudborg.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 453 | ||
| 51 | ||
| 296 | ||
| 495 | ||
| 181 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt